DOI: 10.5281/zenodo.21267283

View latest PathMap Research

DISCLAIMER: This data is not peer reviewed and is NOT professional advice.
Original Text Evaluated

If RGNEF fails agitate and regulate TDP-43 at the RGNEF NF242 Terminal, does this cause TDP-43 propteinopathy?

Plausibility Verdicts

Evaluation 1

Yes, evidence suggests that RGNEF and TDP-43 co-aggregate in ALS, and the NF242 domain of RGNEF is critical for regulating TDP-43. Dysfunction in this regulatory interaction is linked to disease progression.

Evaluation 2

The literature confirms that the NF242 fragment of RGNEF regulates TDP-43, and failure of this mechanism contributes to pathological protein accumulation.

Dataset Summary

Novel & Overlooked Insights

  • TDP-43 and RGNEF co-aggregation serves as a core pathogenic pathway, not just an incidental finding.
  • The N-terminal fragment of RGNEF (NF242) acts as a potential therapeutic agent by competing with RNA for TDP-43 binding sites.
  • Metabolic stress induces the formation of micronuclei where TDP-43 and RGNEF co-aggregate, potentially acting as a mechanism for inclusion formation.
  • RGNEF functions as a guanine nucleotide exchange factor (GEF) and an RNA-binding protein that destabilizes neurofilament light chain mRNA.
  • Genetic loss-of-function in ARHGEF28 (the RGNEF gene) is associated with ALS cases.
  • The interaction between TDP-43, FUS, and RGNEF is part of a complex regulatory network potentially managed by miRNAs like miR-b2122.
  • RGNEF inclusions also colocalize with other proteins including ubiquitin and p62/sequestosome-1.
  • RGNEF and TDP-43 co-localize not only in cytoplasmic inclusions but also within micronuclei, suggesting a nuclear-to-cytoplasmic pathogenic pathway.
  • The leucine-rich domain of RGNEF is critical for its localization in micronuclei during metabolic stress.
  • NF242 interaction with TDP-43 competes directly with RNA binding, proposing a "competitive inhibition" model of toxic aggregation.
  • Rare coding variants in ARHGEF28 are marginally enriched in sALS patients, pointing to a direct genetic susceptibility beyond protein-protein interaction.
  • MiR-b2122 acts as a central regulator of the TDP-43/FUS/RGNEF network, and its down-regulation in sALS patients may synchronize the failure of these proteins.
  • RGNEF also regulates the expression of axon guidance genes, suggesting that the clinical impact of its aggregation extends beyond neurofilament homeostasis.
  • RGNEF acts as a bi-functional protein, functioning as both a guanine nucleotide exchange factor and an RNA-binding protein.
  • RGNEF inclusions and TDP-43 inclusions co-localize in the spinal motor neurons of ALS patients.
  • The leucine-rich domain of RGNEF is critical for its interaction with TDP-43 and its localization within micronuclei.
  • Metabolic stress can induce the formation of TDP-43 inclusions within micronuclei, where they co-aggregate with RGNEF.
  • Genetic expression of the NF242 fragment in a fruit fly ALS model suppressed neuropathological phenotypes and increased lifespan.
  • Transcriptomic profiles of neuronal cells depleted of both TDP-43 and RGNEF show that these factors act antagonistically on axon guidance genes.
  • A novel miRNA, miR-b2122, down-regulates TARDBP, FUS/TLS, and RGNEF, suggesting a common regulatory network.
  • RGNEF binds low-molecular-weight neurofilament mRNA and regulates its stability via the 3' untranslated region.

Extracted Discoveries

Suggested Experiments
  • Quantify TDP-43 aggregation levels in cell lines where the RGNEF IPT/TIG domain is specifically deleted or mutated.
  • Determine the effect of NF242-mimetic peptide treatment on the solubility of phosphorylated TDP-43 in patient-derived iPSC motor neurons.
  • Assess the binding affinity of NF242 variants with mutations in the IPT/TIG domain to TDP-43 in cell-free systems.
  • Perform RNA-seq on motor neurons depleted of RGNEF in the presence or absence of exogenous NF242 to identify rescued axon guidance gene expression profiles.
  • Assess the binding affinity of mutated NF242 domains to TDP-43 using surface plasmon resonance (SPR).
  • Quantify the correlation between levels of endogenous NF242 and TDP-43 aggregate clearance in human iPSC-derived motor neurons.
Suggested Studies
  • Longitudinal study of ARHGEF28 genetic variants to determine correlation with early-onset TDP-43 proteinopathy.
  • Interaction mapping between the RGNEF N-terminal domain and phosphorylated vs. non-phosphorylated forms of TDP-43.
  • Longitudinal study of ARHGEF28 mutation carriers to determine the correlation between onset of TDP-43-positive inclusions and NF242 regulatory failure.
  • Comprehensive screening of miRNA-b2122 levels in FTD/ALS cohorts to determine if low expression correlates with RGNEF/TDP-43 co-aggregation patterns.
  • Longitudinal study comparing RGNEF fragment levels in CSF of pre-symptomatic vs. symptomatic ALS patients.
  • Comprehensive analysis of the RGNEF-TDP-43 regulatory axis in non-ALS TDP-proteinopathies.
Swansons Literature Based Discovery Candidates
  • RGNEF-mediated regulation of axonal transport may preserve the stability of the neuronal cytoskeleton in regions prone to TDP-43-dependent cryptic exon splicing.
  • RGNEF as a regulator of Rho-family GTPases and neurofilament mRNA stability (ID 22835604).
  • TDP-43-dependent regulation of axon guidance genes via long-intron removal and cryptic exon splicing (ID 39360635).
  • RNA-binding and regulation of neurofilament/axon guidance protein expression levels.
  • Both proteins co-aggregate and are critical for RNA metabolism. The combined loss of function may synergistically impair the translation of cytoskeletal proteins, thus accelerating neurodegeneration.
  • RGNEF-mediated regulation of axonal guidance mRNA stability is a upstream protective mechanism that, when disrupted by miRNA-b2122 deficiency, promotes axonal retraction prior to TDP-43 aggregation.
  • Role of RGNEF in axon guidance gene expression (39360635).
  • Down-regulation of miR-b2122 in ALS (28969660).
  • RGNEF (ARHGEF28) 3' UTR binding target.
  • Since miRNA-b2122 regulates RGNEF expression and RGNEF itself regulates axon guidance genes, the miRNA-induced down-regulation of RGNEF likely depletes the axonal mRNA stability pool, creating a vulnerable neuronal environment conducive to subsequent TDP-43 aggregation.
  • RGNEF-mediated NF242 availability acts as a sensor for metabolic stress in determining mitochondrial protein degradation.
  • RGNEF-TDP-43 interaction and NF242 regulatory role (ID: 38739752).
  • Cuproptosis and mitochondrial proteotoxic stress (ID: 42418063).
  • FDX1/LIPT1-related mitochondrial proteotoxic stress and protein aggregation.
  • Since NF242 prevents TDP-43 protein sequestration, and copper-induced lipoylated protein aggregation drives cuproptosis, it is hypothesized that NF242 might mitigate mitochondrial stress by preventing the co-aggregation of proteins like TDP-43 during copper dysregulation.
Contradictions Between Evidences
  • No direct contradictions found; papers consistently support a synergistic pathogenic role for RGNEF and TDP-43.
  • There is a tension between evidence suggesting RGNEF inclusions are causative of ALS (ID: 22835604) and evidence suggesting RGNEF fragments (NF242) are therapeutic (ID: 38739752).
  • None identified within the current provided context.
Repurposed Solutions
  • The RGNEF N-terminal fragment (NF242) is identified as a therapeutic agent to prevent TDP-43 aggregation and neurotoxicity.
  • Use of N-terminal fragments of RGNEF (NF242) to competitively inhibit TDP-43 aggregation in patients carrying ARHGEF28 mutations.
  • Use of NF242 as a therapeutic fragment to target TDP-43 aggregates in multiple proteinopathies.
Support open science: Order your own dataset here.

Perfect for thesis ideas and a base concept for academic writings!

Each package comes with guaranteed unpublished discoveries!

Order now - $29.99

PathMap is funded by sales of datasets and coversheets to researchers of any kind who wish to discover the most viable routes and paths to accelerate cures. We do not make theoretical molecules, we expose the truth in current PubMed literature. Commission a trace today.

Investigator Profile

👨‍🔬
Joshua Dungan
PathMap Admin
PathMap PathMap Image